Anthropic's Long-Term Benefit Trust appointed Novartis CEO Vas Narasimhan to the company's Board of Directors on April 14, 2026, tilting board control toward Trust-selected seats as the AI developer scales. Narasimhan, a physician-scientist who runs one of the world's largest pharmaceutical companies, has overseen the approval of more than 35 novel medicines during his career. With his seat filled, Trust-appointed directors now form a majority of Anthropic's seven-person board.
The addition places Narasimhan alongside Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell. Anthropic is a Public Benefit Corporation, and its board is elected jointly by stockholders and the Long-Term Benefit Trust, an independent body whose members hold no financial stake in the company. The Trust exists to keep Anthropic's governance balanced between commercial returns and its public benefit mandate.
The hiring signal is deliberate. Narasimhan runs Novartis, which operates under some of the strictest regulatory regimes on the planet, and Anthropic's co-founder Daniela Amodei framed the fit exactly that way. "Vas brings something rare to our board. He's overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries," she said. "Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic."
Key facts
- 01Anthropic's Long-Term Benefit Trust appointed Novartis CEO Vas Narasimhan to the Board of Directors on April 14, 2026.
- 02Narasimhan has overseen the development and approval of more than 35 novel medicines during his career at Novartis.
- 03With the appointment, Trust-appointed directors now hold a majority of Anthropic's seven-seat board.
- 04He joins Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell on the board.
- 05Narasimhan is a US National Academy of Medicine member and previously chaired the Pharmaceutical Research and Manufacturers of America.
Narasimhan said he sees a direct parallel between drug development and frontier AI. "In healthcare, AI is accelerating solutions to some of the hardest scientific challenges, from deepening our understanding of disease biology to designing better medicines," he said. He described Anthropic as setting the standard for how AI should be developed to benefit humanity.
“Narasimhan has overseen the development and approval of more than 35 novel medicines at Novartis, one of the most regulated industries on the planet.”— Jaeden Schafer
His background reaches beyond pharmaceutical operations. Early in his career, Narasimhan worked on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America. He is an elected member of the US National Academy of Medicine, sits on the Council on Foreign Relations, serves on the University of Chicago board of trustees, and holds a seat on the board of fellows at Harvard Medical School. He previously chaired the Pharmaceutical Research and Manufacturers of America and remains on its board.
The Trust's chair, Neil "Buddy" Shah, framed the appointment as central to the governance structure's original purpose. "The Long-Term Benefit Trust's role is to appoint directors who will ensure Anthropic responsibly balances its commitment to stockholders and its public benefit mission as the company grows," Shah said. "Vas has spent his career stewarding breakthrough science responsibly — exactly the perspective we are excited to have on the board as we develop consequential technology."
The timing matters. Anthropic has spent the last several weeks stacking up commercial commitments — the multi-gigawatt TPU buildout with Google and Broadcom we covered earlier this month, the launch of Claude Opus 4.7, and the rollout of Claude Design. Adding a sitting pharmaceutical CEO to oversee that expansion is a governance-side counterweight to a very fast commercial-side cadence.
It also reflects where Anthropic sees Claude's enterprise pull. Healthcare and life sciences sit near the top of the company's stated priority markets for applied AI, and Narasimhan's portfolio — drug discovery, regulatory strategy, global health access — is essentially a map of where AI companies want large-contract design partners. Having that voice inside the boardroom gives Anthropic a direct line into one of its hardest-to-sell verticals.
The counterweight question is whether a Trust-majority board genuinely constrains commercial pressure once Anthropic's revenue and fundraising scale keep climbing. Trust members hold no equity, but the board still answers to stockholders on financial questions, and Public Benefit Corporation status has never been stress-tested on a company growing at Anthropic's current rate. Narasimhan's appointment strengthens the mission side of the ledger, but it doesn't rewrite the underlying tension.
The AI Chat Daily take: Anthropic keeps acting like a company that believes its governance structure will eventually be scrutinized — by regulators, by customers, and by its own employees. Putting a pharmaceutical CEO with 35 drug approvals behind him onto a Trust-majority board is the kind of move that reads well in a congressional hearing and in an enterprise procurement meeting. Whether it changes outcomes when the commercial and safety sides disagree is the part no press release can answer.
Working on something we should cover, or seeing a story we missed? Send leads, documents, or feedback to hello@aichatdaily.com. For sensitive tips, see our secure tips page for Signal and PGP options.
Spotted an error? Email hello@aichatdaily.com with the URL and the issue, or read our full corrections policy.
